A rational approach to guide cost-effective de novo donor-specific antibody surveillance with tacrolimus immunosuppression
Immunosuppression
Subclinical infection
DOI:
10.1016/j.ajt.2023.07.025
Publication Date:
2023-08-04T07:40:09Z
AUTHORS (13)
ABSTRACT
De novo DSA (dnDSA) after renal transplantation has been shown to correlate with antibody-mediated rejection and allograft loss. However, the lack of proven interventions time cost associated annual screening for dnDSA are difficult justify all recipients. We studied a well-characterized consecutive cohort (n=949) over fifteen years prospective surveillance identify risk factors that would help institute resource-responsible strategy. Younger recipient age HLA-DR/DQ molecular mismatch were independent predictors development. Combining both into Recipient Age Molecular Mismatch (RAMM) categories we found 52% recipients could be categorized as low-risk development (median subclinical dnDSA-free survival at 5 10 98% 97%). After adjustment, multivariate correlates included tacrolimus versus cyclosporin maintenance immunosuppression (HR 0.37, 95%CI 0.2-0.6, p<0.0001), RAMM category intermediate low 2.48, 1.5-4.2, p=0.0007), high 2.56, 1.6-4.2, p=0.0002), 6.36, 3.7-10.8, p<0.00001). When combined, provide novel data-driven approach reduce testing by >50% while selecting those most likely benefit from surveillance.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (11)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....